← Back to Search

PD-1 Blockade

Tazemetostat + PD-1 Blockade for Non-Small Cell Lung Cancer

Phase 1 & 2
Waitlist Available
Led By Daniel S Shin, MD PhD
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Female subjects of childbearing/reproductive potential must have a negative pregnancy test and use adequate contraception
ECOG 0-1
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial is testing a combination of two drugs to treat patients with advanced non-small cell lung cancer who have progressed from front or second-line treatment. The trial will enroll patients at multiple Veterans Affairs Medical Centers.

Who is the study for?
This trial is for adults with advanced non-small cell lung cancer who've seen their disease progress after anti-PD-1/L1 therapy. They must have good performance status (ECOG 0-1), provide a tumor tissue sample, and have measurable disease. Adequate organ function and agreement to use contraception are required. Those with certain infections, recent major surgery, active pneumonitis or autoimmune diseases, other cancers within 3 years, or severe hypersensitivity to pembrolizumab can't participate.Check my eligibility
What is being tested?
The study tests the combination of Tazemetostat (an EZH2 inhibitor) and Pembrolizumab (a checkpoint blockade therapy) in patients with advanced non-small cell lung cancer at multiple Veterans Affairs Medical Centers. It's an open-label phase Ib/II trial where all participants receive the same treatment without a comparison group.See study design
What are the potential side effects?
Potential side effects include immune-related reactions such as inflammation in various organs, infusion reactions from Pembrolizumab, fatigue, blood disorders like changes in white cells counts which may increase infection risk; liver enzyme alterations could indicate liver issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am not pregnant and will use birth control during the trial.
Select...
I am fully active or can carry out light work.
Select...
My cancer has worsened despite treatment with an anti-PD-1/L1 drug.
Select...
I am a man who can father children and agree to use birth control and not donate sperm.
Select...
I have provided a sample of my tumor that has not been treated with radiation.
Select...
My cancer can be measured by scans.
Select...
My blood tests for kidney, liver, and clotting are within normal ranges.
Select...
I have received more than 30 Gy of radiation therapy in the last 6 months.
Select...
I am 18 or older with advanced lung cancer that has worsened after treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Objective Response Rate (ORR)
Safety and Tolerability
Secondary outcome measures
Disease control rate (DCR)
Duration of Response (DOR)
Progression Free Survival (PFS) and 1-year survival rate

Side effects data

From 2021 Phase 2 trial • 20 Patients • NCT03456726
53%
Dysgeusia
41%
Nasopharyngitis
29%
Upper respiratory tract infection
29%
Blood creatine phosphokinase increased
29%
Lymphopenia
29%
Constipation
29%
Stomatitis
24%
Rash
18%
Neutropenia
18%
Blood creatinine increased
18%
Weight decreased
18%
Thrombocytopenia
18%
Nausea
12%
Pneumonia
12%
Amylase increased
12%
Herpes simplex
12%
Urinary tract infection
12%
Influenza
12%
Malaise
12%
Hypertriglyceridaemia
12%
Anaemia
12%
Hypophosphataemia
12%
Alopecia
12%
Eczema
6%
Aspartate aminotransferase increased
6%
Upper respiratory tract inflammation
6%
Oedema peripheral
6%
Blood pressure decreased
6%
Pyrexia
6%
Blood zinc decreased
6%
Immature granulocyte count increased
6%
Hypoalbuminaemia
6%
Rash maculo-papular
6%
Alanine aminotransferase increased
6%
Traumatic intracranial haemorrhage
6%
Haematochezia
6%
Impetigo
6%
Non-small cell lung cancer
6%
Electrocardiogram QT prolonged
6%
Abdominal pain
6%
Large intestine polyp
6%
Tooth disorder
6%
Hypogammaglobulinaemia
6%
Bronchitis
6%
Gastroenteritis
6%
Insomnia
6%
Visual field defect
6%
Gamma-glutamyltransferase increased
6%
Musculoskeletal chest pain
6%
Phlebitis
6%
Haematuria
6%
Hypertonic bladder
6%
Nail disorder
6%
Skin exfoliation
6%
Gastric cancer
6%
Myalgia
6%
Osteonecrosis of jaw
6%
Pneumocystis jirovecii pneumonia
6%
Traumatic fracture
6%
Fatigue
6%
Cataract
6%
Mechanical ileus
6%
Atypical pneumonia
6%
Periodontitis
6%
Pneumonia aspiration
6%
Leukopenia
6%
Pericardial effusion
6%
Conjunctival haemorrhage
6%
Visual impairment
6%
Epigastric discomfort
6%
Oral herpes
6%
Paronychia
6%
Fall
6%
Postoperative delirium
6%
Procedural pain
6%
Skin laceration
6%
Tooth fracture
6%
Hyperglycaemia
6%
Hyperkalaemia
6%
Hyperuricaemia
6%
Pain in extremity
6%
Tendon disorder
6%
Myelodysplastic syndrome
6%
Muscle spasticity
6%
Peripheral motor neuropathy
6%
Sciatica
6%
Syncope
6%
Asthma
6%
Dysphonia
6%
Erythema multiforme
6%
Keloid scar
100%
80%
60%
40%
20%
0%
Study treatment Arm
Participants With Follicular Lymphoma
Participants With Diffuse Large B-cell Lymphoma

Trial Design

1Treatment groups
Experimental Treatment
Group I: combination of tazemetostat and pembrolizumabExperimental Treatment1 Intervention
Enrolled patients will receive combination treatment for whole study duration (2 years). For first cycle, patient will start tazemetostat one week prior to start every 3 week pembrolizumab intravenous infusion (pembrolizumab will be given day 8 only for the first cycle, rest of cycles will be day 1 of each cycle).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tazemetostat
2016
Completed Phase 2
~780

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,605 Previous Clinical Trials
3,305,530 Total Patients Enrolled
VA Greater Los Angeles Healthcare SystemFED
51 Previous Clinical Trials
8,503 Total Patients Enrolled
Daniel S Shin, MD PhDPrincipal InvestigatorVA Greater Los Angeles Healthcare System, West Los Angeles, CA

Media Library

Pembrolizumab (PD-1 Blockade) Clinical Trial Eligibility Overview. Trial Name: NCT05467748 — Phase 1 & 2
Non-Small Cell Lung Cancer Research Study Groups: combination of tazemetostat and pembrolizumab
Non-Small Cell Lung Cancer Clinical Trial 2023: Pembrolizumab Highlights & Side Effects. Trial Name: NCT05467748 — Phase 1 & 2
Pembrolizumab (PD-1 Blockade) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05467748 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any unfilled spots in this experiment that I could take part in?

"Unfortunately, this study is not currently enrolling patients. The listing was first posted on January 2nd 2023 but the most recent update was on October 12th 2022. Although there are no plans to recruit at the moment, there are 2098 other trials that are still looking for volunteers."

Answered by AI
~44 spots leftby May 2025